<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0708222417
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ORFADIN 5 MG CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NITISINONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        6169.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEK PRODUKTION &amp; LABORATORIER AB" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEK PRODUKTION & LABORATORIER AB
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 594]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Arabian Trade House
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SWEDISH ORPHAN BIOVITRUM INTERNATIONAL AB
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A16AX04 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Orfadin contains the active substance nitisinone. Orfadin is used to treat:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a rare disease called hereditary tyrosinemia type 1 in adults, adolescents and children (in any age range)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a rare disease called alkaptonuria (AKU) in adults</p><p>&nbsp;</p><p>In these diseases your body is unable to completely break down the amino acid tyrosine (amino acids are building blocks of our proteins), forming harmful substances. These substances are accumulated in your body. Orfadin<sup> </sup>blocks the breakdown of tyrosine and the harmful substances are not formed.</p><p>&nbsp;</p><p>For the treatment of hereditary tyrosinemia type 1, you must follow a special diet while you are taking this medicine, because tyrosine will remain in your body. This special diet is based on low tyrosine and phenylalanine (another amino acid) content.</p><p>&nbsp;</p><p>For the treatment of AKU, your doctor may advice you to follow a special diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Orfadin</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to nitisinone or any of the other ingredients of this medicine (listed in&nbsp;section 6).</p><p>&nbsp;</p><p>Do not breast-feed while taking this medicine, see section &ldquo;Pregnancy and breast-feeding&rdquo;.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Orfadin.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your eyes will be checked by an ophthalmologist before and regularly during nitisinone treatment. If you get red eyes or any other signs of effects on the eyes, contact your doctor immediately for an eye examination. Eye problems could be a sign of inadequate dietary control (see section 4).</p><p>&nbsp;</p><p>During the treatment, blood samples will be drawn in order for your doctor to check whether the treatment is adequate and to make sure that there are no possible side effects causing blood disorders.</p><p>&nbsp;</p><p>If you receive Orfadin for treatment of hereditary tyrosinemia type 1, your liver will be checked at regular intervals because the disease affects the liver.</p><p>&nbsp;</p><p>Follow-up by your doctor should be performed every 6 months. If you experience any side effects, shorter intervals are recommended.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Orfadin</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Orfadin may interfere with the effect of other medicines, such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for epilepsy (such as phenytoin)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines against blood clotting (such as warfarin)</p><p><strong>&nbsp;</strong></p><p><strong>Orfadin with food</strong></p><p>If you start treatment by taking it with food, it is recommended that you carry on taking it with food throughout your course of treatment.</p><p>&nbsp;</p><p><strong>Pregnancy and breast‑feeding</strong></p><p>The safety of this medicine has not been studied in pregnant and breast-feeding women.</p><p>Please contact your doctor if you plan to become pregnant. If you become pregnant you should contact your doctor immediately.</p><p>Do not breast-feed while taking this medicine, see section &ldquo;Do not take Orfadin&rdquo;.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>This medicine has minor influence on the ability to drive and use machines. However, if you experience side effects affecting your vision you should not drive or use machines until your vision is back to normal (see section 4&ldquo;Possible side effects&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>For hereditary tyrosinemia type 1, treatment with this medicine should be started and supervised by a doctor experienced in the treatment of the disease.</p><p>&nbsp;</p><p>For hereditary tyrosinemia type 1, the recommended total daily dose is 1&nbsp;mg/kg body weight administered orally. Your doctor will adjust the dose individually.</p><p>It is recommended to administer the dose once daily. However, due to the limited data in patients with body weight &lt;20&nbsp;kg, it is recommended to divide the total daily dose into two daily administrations in this patient population.</p><p>&nbsp;</p><p>For AKU, the recommended dose is 10&nbsp;mg once daily.</p><p>&nbsp;</p><p>If you have problems with swallowing the capsules, you may open the capsule and mix the powder with a small amount of water or formula diet just before you take it.</p><p>&nbsp;</p><p><strong>If you take more Orfadin</strong> <strong>than you should</strong></p><p>If you have taken more of this medicine than you should, contact your doctor or pharmacist as soon as possible.</p><p>&nbsp;</p><p><strong>If you forget to take Orfadin</strong></p><p>Do not take a double dose to make up for a forgotten dose. If you forget to take a dose, contact your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>If you stop taking Orfadin</strong></p><p>If you have the impression that the medicine is not working properly, talk to your doctor. Do not change the dose or stop the treatment without talking to your doctor.</p><p><strong>&nbsp;</strong></p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If you notice any side effects relating to the eyes, talk to your doctor immediately to have an eye examination. Treatment with nitisinone leads to higher levels of tyrosine in the blood which can cause eye related symptoms. In patients with hereditary tyrosinemia type 1, commonly reported eye related side effects (may affect more than 1 in 100 people) caused by higher tyrosine levels are inflammation in the eye (conjunctivitis), opacity and inflammation in the cornea (keratitis), sensitivity to light (photophobia) and eye pain. Inflammation of the eyelid (blepharitis) is an uncommon side effect (may affect up to 1 in 100 people).</p><p>In AKU patients, eye irritation (keratopathy) and eye pain are very commonly reported side effects (may affect more than 1 in 10 people).</p><p>&nbsp;</p><p><strong>Other </strong><strong>side effects reported in patients with hereditary tyrosinemia type 1 are listed below:</strong></p><p>&nbsp;</p><p><u>Other common side effects</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced number of platelets (thrombocytopenia) and white blood cells (leukopenia), shortage of certain white blood cells (granulocytopenia).</p><p>&nbsp;</p><p><u>Other uncommon side effects </u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased number of white blood cells (leucocytosis),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching (pruritus), skin inflammation (exfoliative dermatitis), rash.</p><p>&nbsp;</p><p><strong>Other side effects reported in patients with AKU are listed below:</strong></p><p>&nbsp;</p><p><u>Other common side effects</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bronchitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pneumonia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching (pruritus), rash</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;margin-left:8.3pt;margin-top:30.55pt;
 width:435.75pt;height:68.1pt;z-index:251657728;visibility:visible;
 mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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"/><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>The National Pharmacovigilance and Drug Safety Centre (NPC):</p><p>o SFDA Call Center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p><u>To reports any side effect(s):</u><br />&middot; <strong><em>Saudi Arabia</em></strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><br />&nbsp;</p><p>&middot; <strong><em>Other GCC States:</em></strong></p><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_1"
 o:spid="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
 margin-left:-3.7pt;margin-top:1.4pt;width:441pt;height:21.6pt;z-index:251658752;
 visibility:visible;mso-width-relative:margin;mso-height-relative:margin'
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>- Please contact the relevant competent authority.</p></td></tr></tbody></table></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the bottle and the carton after &ldquo;EXP&rdquo;.</p><p>The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).<br />The medicine can be stored for a single period of 2&nbsp;months (for 2 mg capsules) or 3 months (for 5 mg, 10 mg and 20 mg capsules) at a temperature not above 25&deg;C, after which it must be discarded.</p><p>&nbsp;</p><p>Do not forget to mark the date on the bottle, when removed from the refrigerator.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Orfadin contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is nitisinone.</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Orfadin 2&nbsp;mg:</em><strong> </strong>Each capsule contains 2&nbsp;mg nitisinone.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Orfadin</em><em> 5&nbsp;mg</em><em>:</em><strong> </strong>Each capsule contains 5&nbsp;mg nitisinone.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Orfadin</em><em> 10&nbsp;mg</em><em>:</em><strong> </strong>Each capsule contains 10&nbsp;mg nitisinone.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Orfadin 20&nbsp;mg:</em><strong> </strong>Each capsule contains 20 mg nitisinone.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Capsule content: </u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; starch, pregelatinised (maize).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Capsule shell: </u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gelatine</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; titanium dioxide (E 171).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Printing ink: </u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; iron oxide (E 172)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shellac</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; propylene glycol</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ammonium hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
The hard capsules are white, opaque, imprinted with “NTBC” and the strength “2 mg”, “5 mg”, “10 mg” or “20 mg”, in black. The capsule contains a white to off-white powder.


The capsules are packaged in plastic bottles with tamper‑proof closures. Each bottle contains 60 capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Swedish Orphan Biovitrum International AB</p><p>SE-112 76 Stockholm</p><p>Sweden</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Apotek Produktion &amp; Laboratorier AB</p><p>Prismav&auml;gen 2</p><p>SE-141 75 Kungens Kurva</p><p>Sweden</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 22/10/2020

THIS IS A MEDICAMENT
•	Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.
•	Follow strictly the doctor's prescription, the method of use and the instructions of the pharmacist who sold the medicament. 
•	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
•	Do not by yourself interrupt the period of treatment prescribed.
•	Do not repeat the same prescription without consulting your doctor.
•	Keep all medicaments out of the reach of children.

Council of Arab Health Ministers, Union of Arab Pharmacists
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي أورفادين على المادة الفعالة نيتيسينون. أورفادين يُستخدم في علاج:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرضٍ نادر يُطلق عليه فرط تيروزين الدم الوراثي من النوع الأول يُصاب به البالغون والمراهقون والأطفال (في أي مرحلة عمرية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض يسمى بيلة ألكابتونية (AKU) في البالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت بهذه الأمراض لا يستطيع جسمك تكسير الحمض الأميني تيروزين تمامًا (الأحماض الأمينية هي وحدة بناء البروتين في أجسامنا)، مما يتسبب في تكون مواد ضارة. وتتراكم هذه المواد في جسمك. ويعمل أورفادين<sup> </sup>على منع تكسير التيروزين وبهذا لا تتكون المواد الضارة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لعلاج مرض فرط تيروزين الدم الوراثي من النوع الأول، يجب عليك اتباع نظام غذائي خاص أثناء تناول هذا الدواء؛ نظرًا لأن التيروزين سيبقى في جسمك. ويعتمد هذا النظام الغذائي الخاص على محتوى منخفض من حمض تيروزين وفينيل ألانين (حمض أميني آخر).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لعلاج مرض البيلة ألكابتونية (AKU) ، قد ينصحك طبيبك باتباع نظام غذائي خاص.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تجنب تناول دواء أورفادين</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت تُعاني من حساسية تجاه مادة نيتيسينون أو أي من المواد الأخرى التي يتكون منها هذا الدواء (الواردة في القسم 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب على الأم تجنب الرضاعة الطبيعية أثناء تناول هذا الدواء، راجع قسم &quot;الحمل والرضاعة الطبيعية&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">استشر الطبيب أو الصيدلاني قبل تناول دواء أورفادين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيتم فحص عينيك من قبل طبيب العيون قبل وبانتظام اثناء العلاج بالنيتيسينون، إذا أُصبت باحمرار العينين أو ظهرت عليك علامات أخرى لتأثر العينين، اتصل بالطبيب على الفور لتحديد موعد لفحص العين. قد تكون مشكلات العين علامة على عدم التحكم في النظام الغذائي بشكل كافٍ (راجع القسم 4).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثناء فترة العلاج، سيتم سحب عينات دم يستخدمها طبيبك المُعالج ليتحقق من مدى كفاية العلاج ويتأكد من عدم وجود آثار جانبية محتملة تسبب اضطرابات في الدم.</p><p dir="RTL">إذا كنت تتلقى أورفادين لعلاج مرض فرط تيروزين الدم الوراثي من النوع الأول، سيتم فحص الكبد على فترات فاصلة منتظمة؛ نظرًا لأن المرض يؤثر على الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب إجراء المتابعة بواسطة طبيبك المُعالج كل 6 أشهر. إذا كنت تعاني من أي آثار جانبية، فيوصى بزيارة الطبيب على فترات فاصلة أقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وأورفادين</strong></p><p dir="RTL">الرجاء إخبار طبيبك أو الصيدلاني إن كنت تتناول أو تناولت مؤخرًا أو يحتمل أن تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أورفادين من المحتمل أن يتعارض مع تأثير بعض الأدوية، مثل:</p><p dir="RTL">- أدوية علاج الصرع (مثل فينيتوين)</p><p dir="RTL">- الأدوية المضادة لتخثر الدم (مثل الوارفارين)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول دواء أورفادين مع الطعام</strong></p><p dir="RTL">إذا بدأت العلاج بتناول دواء أورفادين مع الطعام، فيوصى بمتابعة تناوله مع الطعام طوال فترة العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لم تتم دراسة مدى أمان هذا الدواء على النساء الحوامل واللاتي يُرضعن أطفالهن رضاعة طبيعية.</p><p dir="RTL">الرجاء الاتصال بطبيبك إذا كنتِ تخططين لتصبحين حاملاً. إذا أصبحتِ حاملاً، فيجب أن تتصلي بطبيبك على الفور.</p><p dir="RTL">يجب عليكِ تجنّب الرضاعة الطبيعية أثناء تناول هذا الدواء، راجعي قسم &quot;تجنب تناول دواء أورفادين&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يؤثر هذا الدواء تأثيرًا طفيفًا في القدرة على القيادة واستخدام الآلات. ومع ذلك، إذا كنت تُعاني من آثار جانبية تؤثر على قوة الإبصار لديك، فيجب ألا تقود السيارة أو تستخدم الآلات حتى تسترد قوة الإبصار الطبيعية (راجع القسم 4 بعنوان &quot;الآثار الجانبية المحتملة&quot;).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دومًا وفقًا للطريقة التي يُخبرك بها الطبيب. في حال الشك، يمكنك مراجعة طبيبك أو الصيدلاني.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لعلاج مرض فرط تيروزين الدم الوراثي من النوع الأول، يجب أن يبدأ العلاج بهذا الدواء والإشراف عليه بواسطة طبيب ذي خبرة في علاج المرض (فرط تيروزين الدم الوراثي من النوع الأول).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لعلاج مرض فرط تيروزين الدم الوراثي من النوع الأول، تبلغ الجرعة اليومية الإجمالية الموصى بها 1 ملجم/كجم من وزن الجسم وتؤخذ عن طريق الفم. سيعدّل الطبيب الجرعة بصفة فردية</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينصح بأخذ الجرعة مرة واحدة يومياً ، بالرغم من ذلك و لمحدودية الدراسات الخاصة بالمرضى الذين وزنهم أقل من 20 كجم ينصح بتقسيم الجرعة اليومية الكلية لهذه الفئة من المرضى الى مرتين يومياً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لعلاج مرض البيلة ألكابتونية (AKU)، الجرعة الموصى بها هي 10 ملجم مرة واحدة يومياً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تشعر بصعوبة في بلع الكبسولات، فيمكنك فتح الكبسولة وخلط المسحوق مع كمية قليلة من الماء أو مكمل غذائي قبل تناوله مباشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تتناول أورفادين</strong> <strong>بجرعات كبيرة أكثر مما ينبغي</strong></p><p dir="RTL">إذا تناولت هذا الدواء بجرعات كبيرة أكثر مما ينبغي، فاتصل بطبيبك أو الصيدلاني في أقرب وقت ممكن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول دواء أورفادين</strong></p><p dir="RTL">لا تأخذ جرعة مضاعفة لتعويض الجرعة التي نسيتها. إذا نسيت تناول إحدى الجرعات، فاتصل بطبيبك أو الصيدلاني.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول دواء أورفادين</strong></p><p dir="RTL">إذا كنت ترى أنّ الدواء لا يعمل على الوجه الصحيح، فاستشر طبيبك. لا تُغيّر الجرعة أو توقف العلاج دون استشارة طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي اسئلة أخرى حول استخدام هذا الدواء، فاطرحها على طبيبك أو الصيدلاني أو الممرض.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يتسبب هذا الدواء في الإصابة بآثار جانبية رغم أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت ظهور أي آثار جانبية ترتبط بالعينين، فاستشر طبيبك على الفور ليفحص عينيك. يتسبب العلاج بمادة نيتيسينون في ارتفاع مستويات التيروزين في الدم والذي يمكن أن يتسبب في ظهور أعراض مرتبطة بالعين. للمرضى المصابين بمرض فرط تيروزين الدم الوراثي من النوع الأول، &nbsp;تظهر الآثار الجانبية التي يتم الإبلاغ عنها بشكل شائع ذات الصلة بالعين (قد تؤثر على أكثر من 1 في كل 100 أشخاص) والتي سببها ارتفاع مستويات التيروزين في صورة التهاب العين (التهاب الملتحمة) وحالة من الضبابية والالتهاب تصيب القرنية (التهاب القرنية) وحساسية تجاه الضوء (رهاب الضوء) وألم في العين. ويُعد أيضًا التهاب جفن العين (تشنج الجفن) من الآثار الجانبية غير الشائعة (قد يؤثر على 1 في كل 100 شخص).</p><p dir="RTL">&nbsp;</p><p dir="RTL">في مرضى البيلة ألكابتونية (AKU) ، يتم الإبلاغ عن تهيج العين (اعتلال القرنية) وآلام العين بشكل شائع (قد تؤثر على أكثر من 1 من كل 10 أشخاص).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى التي تم الإبلاغ عنها في المرضى الذين يعانون من </strong><strong>فرط تيروزين الدم الوراثي من النوع الأول</strong><strong> مذكورة أدناه:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الآثار الجانبية الشائعة الأخرى</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح (نقص الصفائح الدموية) وخلايا الدم البيضاء (نقص الكريات البيضاء) ونقص في خلايا دم بيضاء معيّنة (نقص المحببات).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الآثار الجانبية غير الشائعة الأخرى </u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة عدد خلايا الدم البيضاء (كثرة الكريات البيضاء) و</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكّة (الهرش) والتهاب الجلد (التهاب الجلد التقشري) والطفح الجلدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى التي تم الإبلاغ عنها في مرضى البيلة ألكابتونية (</strong><strong>AKU</strong><strong>) مذكورة أدناه:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الشائعة الأخرى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; التهاب شعبي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; التهاب رئوي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; حكة (حكة) ، طفح جلدي</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية</p><p dir="RTL">مركز الاتصال الموحد للهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">البريد الإلكتروني: <strong>npc.drug@sfda.gov.sa</strong></p><p dir="RTL">الموقع الإلكتروني: <strong>https://ade.sfda.gov.sa/</strong></p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى: </strong></p><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الرجاء حفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد انقضاء فترة صلاحيته، المذكورة على الزجاجة والكرتون بعد الرمز &quot;EXP&quot;.</p><p dir="RTL">ويشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الرجاء تخزين الدواء في الثلاجة (من 2 إلى 8 درجات مئوية).<br />يمكن تخزين الدواء لفترة واحدة تبلغ شهرين (لكبسولات 2 ملجم) أو فترة 3 أشهر (لكبسولات 5 ملجم ، 10 ملجم و 20 ملجم) في درجة حرارة لا تزيد عن 25 درجة مئوية ويجب التخلص من الدواء بعدها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تنسَ وضع علامة على التاريخ الموجود على العبوة عند إخراج الدواء من الثلاجة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية بإلقائها في مياه الصرف الصحي أو المخلفات المنزلية. الرجاء مراجعة الصيدلاني حول كيفية التخلص من الأدوية التي لم تعد تستخدمها. تساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي نيتيسينون.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>أورفادين 2 ملجم:</em><strong> </strong>تحتوي كل كبسولة على 2 ملجم من مادة نيتيسينون.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>أورفادين 5 ملجم:</em><strong> </strong>تحتوي كل كبسولة على 5 ملجم من مادة نيتيسينون.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>أورفادين 10 ملجم:</em><strong> </strong>تحتوي كل كبسولة على 10 ملجم من مادة نيتيسينون.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>أورفادين 20 ملجم:</em><strong> </strong>تحتوي كل كبسولة على 20 ملجم من مادة نيتيسينون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>محتوى الكبسولة: </u></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النشا، مغلفّة بمادة جيلاتينية (من الذرة).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>غطاء الكبسولة: </u></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجيلاتين</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثاني أكسيد التيتانيوم (E 171).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>حبر الطباعة: </u></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أكسيد الحديد (E 172)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اللك المصفى</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جليكول البروبيلين</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيدروكسيد الأمونيوم</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الكبسولات الصلبة تكون بيضاء اللون وغير شفافة ومطبوعًا عليها أحرف &quot;NTBC&quot; والتركيز &quot;&lrm;2 &nbsp;ملجم&quot; أو &quot;5&lrm; ملجم&quot; أو &quot;10&lrm; ملجم&quot; أو &quot;&lrm;20 &nbsp;ملجم&quot;، باللون الأسود. تحتوي الكبسولة على مسحوق بلون أبيض إلى أبيض مائل للصفرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتم تعبئة الكبسولات في زجاجات بلاستيكية مزوّدة بسدادات لا يمكن العبث بها. تحتوي كل زجاجة على 60 كبسولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجهة المخولة بالتسويق</strong></p><p dir="RTL">سويدش اورفان بيوتيرم انتيرناشونال أي بي</p><p dir="RTL">سي 112 76 ستوكهولم</p><p dir="RTL">السويد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنّعة</strong></p><p dir="RTL">أبوتيك برودكشن و لابوراتورير أي بي</p><p dir="RTL">بريسمافاجين 2 &nbsp;</p><p dir="RTL">سي- 141 75 كونجينس كورفا</p><p dir="RTL">السويد</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت المراجعة الأخيرة لهذه النشرة في 22/10/2020

هذا المنتج هو عبارة عن دواء
•	الدواء مستحضر يؤثر على صحتك واستهلاكه خلافاً لذلك يعرضك للخطر.
•	اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرفها لك. 
•	إن الطبيب والصيدلاني هما الخبيران في الدواء وبنفعه وضرره.
•	لا تقطع مدة العلاج الموصوف لك من تلقاء نفسك.
•	لا تكرر صرف الدواء بدون استشارة طبيبك.
•	احفظ كل الأدوية بعيداً عن متناول الأطفال

مجلس وزراء الصحة العرب 
واتحاد الصيادلة العرب

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Orfadin 2 mg hard capsules
Orfadin 5 mg hard capsules
Orfadin 10 mg hard capsules
Orfadin 20 mg hard capsules

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains 2 mg nitisinone.
Each capsule contains 5 mg nitisinone.
Each capsule contains 10 mg nitisinone.
Each capsule contains 20 mg nitisinone.

For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule.
White, opaque capsules (6x16 mm) imprinted “NTBC 2mg” in black on the body of the capsule. 
White, opaque capsules (6x16 mm) imprinted “NTBC 5mg” in black on the body of the capsule.
White, opaque capsules (6x16 mm) imprinted “NTBC 10mg” in black on the body of the capsule.
White, opaque capsules (6x16 mm) imprinted “NTBC 20mg” in black on the body of the capsule.
The capsules contain a white to off white powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hereditary tyrosinemia type 1 (HT‑1)</u></p><p>Orfadin is indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT‑1) in combination with dietary restriction of tyrosine and phenylalanine.</p><p>&nbsp;</p><p><u>Alkaptonuria (AKU)</u></p><p>Orfadin is indicated for the treatment of adult patients with alkaptonuria (AKU).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>HT-1:</p><p>Nitisinone treatment should be initiated and supervised by a physician experienced in the treatment of HT‑1 patients.</p><p>&nbsp;</p><p><strong><em>Treatment of all genotypes of the disease should be initiated as early as possible to increase overall survival and avoid complications such as liver failure, liver cancer and renal disease. </em></strong><strong><em>Adjunct to the nitisinone treatment, a diet deficient in phenylalanine and tyrosine is required and should be followed by monitoring of plasma amino acids (see sections 4.4 and 4.8).</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><em>Starting dose HT-1</em></p><p><strong><em>The recommended initial daily dose in the paediatric and adult population is 1&nbsp;mg/kg body weight administered orally. The dose of nitisinone should be adjusted individually. It is recommended to administer the dose once daily. However, due to the limited data in patients with body weight &lt;20&nbsp;kg, it is recommended to divide the total daily dose into two daily administrations in this patient population.</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong>Dose adjustment HT-1</strong></p><p><strong><em>During regular monitoring, it is appropriate to follow urine succinylacetone, liver function test values and alpha‑fetoprotein levels (see section 4.4). If urine succinylacetone is still detectable one month after the start of nitisinone treatment, the nitisinone dose should be increased to 1.5&nbsp;mg/kg body weight/day. A dose of 2&nbsp;mg/kg body weight/day may be needed based on the evaluation of all biochemical parameters. This dose should be considered as a maximal dose for all patients.</em></strong></p><p><strong><em>If the biochemical response is satisfactory, the dose should be adjusted only according to body weight gain</em></strong>.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>However, in addition to the tests above, during the initiation of therapy, switch from twice daily to once daily dosing or if there is a deterioration, it may be necessary to follow more closely all available biochemical parameters (i.e. plasma succinylacetone, urine 5‑aminolevulinate (ALA) and erythrocyte porphobilinogen (PBG)‑synthase activity). </em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>AKU:</em></strong></p><p><strong><em>Nitisinone treatment should be initiated and supervised by a physician experienced in the treatment of AKU patients.</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>The recommended dose in the adult AKU population is 10 mg once daily.</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><em>Special populations</em></p><p><strong><em>There are no specific dose recommendations for elderly or patients that have renal or hepatic impairment.</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong>Paediatric population</strong></p><p><strong><em>HT-1:</em></strong> <strong><em>The dose recommendation in mg/kg body weight is the same in children and adults.</em></strong></p><p><strong><em>However, due to the limited data in patients with body weight &lt;20&nbsp;kg, it is recommended to divide the total daily dose into two daily administrations in this patient population.</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>AKU: The safety and efficacy of Orfadin in children aged 0 to 18 years with AKU have not been established. No data are available.</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><u>Method of administration</u></p><p><strong><em>The capsule may be opened and the content suspended in a small amount of water or formula diet immediately before intake.</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Orfadin is also available as a 4&nbsp;mg/ml oral suspension for paediatric and other patients who have difficulties swallowing capsules.</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>It is recommended that if nitisinone treatment is initiated with food, this should be maintained on a routine basis, see section 4.5.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Mothers receiving nitisinone must not breast feed (see sections 4.6 and 5.3).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Monitoring visits should be performed every 6 months; shorter intervals between visits are recommended in case of adverse events.</em></strong></p><p>&nbsp;</p><p><strong><em><u>Monitoring of plasma tyrosine levels</u></em></strong></p><p><strong><em>It is recommended that a slit‑lamp examination of the eyes is performed before initiation of nitisinone treatment and thereafter regularly, at least once a year. A patient displaying visual disorders during treatment with nitisinone should without delay be examined by an ophthalmologist. </em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>HT-1: It should be established that the patient is adhering to his/her dietary regimen and the plasma tyrosine concentration should be measured. A more restricted tyrosine and phenylalanine diet should be implemented in case the plasma tyrosine level is above 500&nbsp;micromol/l. It is not recommended to lower the plasma tyrosine concentration by reduction or discontinuation of nitisinone, since the metabolic defect may result in deterioration of the patient&rsquo;s clinical condition.</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>AKU: In patients who develop keratopathies, plasma tyrosine levels should be monitored. A diet restricted in tyrosine and phenylalanine should be implemented to keep the plasma tyrosine level below 500 micromol/l. In addition, nitisinone should be temporarily discontinued and may be reintroduced when the symptoms have been resolved.</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em><u>Liver monitoring</u></em></strong></p><p><strong><em>HT-1: The liver function should be monitored regularly by liver function tests and liver imaging. It is recommended to also monitor serum alpha-fetoprotein </em></strong><strong><em>concentrations. Increase in serum alpha‑fetoprotein concentration </em></strong><strong><em>may be a sign of inadequate treatment. Patients with increasing alpha‑fetoprotein </em></strong><strong><em>or signs of nodules in the liver should always be evaluated for hepatic malignancy.</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em><u>Platelet and white blood cell (WBC) monitoring</u></em></strong></p><p><strong><em>It is recommended that platelet and WBC counts are monitored regularly</em></strong> <strong><em>for both HT-1 and AKU patients, as a few cases of reversible thrombocytopenia and leucopenia were observed during clinical evaluation</em></strong> <strong><em>of HT-1.</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><u>Concomitant use with other medicinal products</u></p><p><strong><em>Nitisinone is a moderate CYP2C9 inhibitor. Nitisinone treatment may therefore result in increased plasma concentrations of co-administered medicinal products metabolized primarily via CYP2C9. Nitisinone treated patients who are concomitantly treated with medicinal products with a narrow therapeutic window metabolized through CYP2C9, such as warfarin and phenytoin, should be carefully monitored. Dose-adjustment of these co-administered medicinal products may be needed (see section 4.5).</em></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nitisinone is metabolised <em>in vitro</em> by CYP&nbsp;3A4 and dose‑adjustment may therefore be needed when nitisinone is co‑administered with inhibitors or inducers of this enzyme.</p><p>&nbsp;</p><p>Based on data from a clinical interaction study with 80 mg nitisinone at steady-state, nitisinone is a moderate inhibitor of CYP2C9 (2.3-fold increase in tolbutamide AUC), therefore nitisinone treatment may result in increased plasma concentrations of co-administered medicinal products metabolized primarily via CYP2C9 (see section 4.4).</p><p>Nitisinone is a weak inducer of CYP2E1 (30% decrease in chlorzoxazone AUC) and a weak inhibitor of OAT1 and OAT3 (1.7-fold increase in AUC of furosemide), whereas nitisinone did not inhibit CYP2D6 (see section 5.2).</p><p>&nbsp;</p><p>No formal food interactions studies have been performed with Orfadin hard capsules. However, nitisinone has been co‑administered with food during the generation of efficacy and safety data. Therefore, it is recommended that if nitisinone treatment with Orfadin hard capsules is initiated with food, this should be maintained on a routine basis, see section 4.2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><u>Pregnancy Category C</u></p><p>There are no adequate data from the use of nitisinone in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Orfadin should not be used during pregnancy unless the clinical condition of the woman requires treatment with nitisinone. Nitisinone crosses the human placenta.</p><p>&nbsp;</p><p>Breast‑feeding</p><p>It is unknown whether nitisinone is excreted in human breast milk. Animal studies have shown adverse postnatal effects via exposure of nitisinone in milk. Therefore, mothers receiving nitisinone<strong><em> </em></strong>must not breast‑feed, since a risk to the suckling child cannot be excluded (see sections 4.3 and 5.3).</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no data on nitisinone affecting fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Orfadin has minor influence on the ability to drive and use machines. Adverse reactions involving the eyes (see section 4.8) can affect the vision. If the vision is affected the patient should not drive or use machines until the event has subsided.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>By its mode of action, nitisinone increases tyrosine levels in all nitisinone treated patients. Eye‑related adverse reactions, such as conjunctivitis, corneal opacity, keratitis, photophobia, and eye pain, related to elevated tyrosine levels are therefore common in both HT-1 and AKU patients. In the HT-1 population other common adverse reactions include thrombocytopenia, leucopenia, and granulocytopenia. Exfoliative dermatitis may occur uncommonly.</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p>The adverse reactions listed below by MedDRA system organ class and absolute frequency, are based on data from clinical trials in patients with HT-1 and AKU and post‑marketing use in HT-1. Frequency is defined as very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:664px"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency in HT-1</strong></p></td><td style="vertical-align:top"><p><strong>Frequency in AKU<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Bronchitis, pneumonia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia, leucopenia, granulocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Leukocytosis</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Conjunctivitis, corneal opacity, keratitis, photophobia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common<sup>2</sup></p></td><td style="vertical-align:top"><p>Keratopathy</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common<sup>2</sup></p></td><td style="vertical-align:top"><p>Eye pain</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blepharitis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Exfoliative dermatitis, erythematous rash</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pruritus, rash</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Elevated tyrosine levels</p></td></tr></tbody></table><p><sup>1</sup>The frequency is based on one clinical study in AKU.</p><p><sup>2</sup>Elevated tyrosine levels are associated with eye-related adverse reaction. Patients in the AKU study did not have a diet restricted in tyrosine and phenylalanine.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>Nitisinone treatment leads to elevated tyrosine levels. Elevated levels of tyrosine have been associated with eye‑related adverse reactions, such as e.g. corneal opacities and hyperkeratotic lesions in HT-1 and AKU patients. Restriction of tyrosine and phenylalanine in the diet should limit the toxicity associated with this type of tyrosinemia by lowering tyrosine levels (see section 4.4).</p><p>In clinical studies of HT-1, granulocytopenia was only uncommonly severe (&lt;0.5x10<sup>9</sup>/L) and not associated with infections. Adverse reactions affecting the MedDRA system organ class &lsquo;Blood and lymphatic system disorders&rsquo; subsided during continued nitisinone treatment.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety profile in HT-1 is mainly based on the paediatric population since nitisinone treatment should be started as soon as the diagnosis of hereditary tyrosinemia type 1 (HT‑1) has been established. From clinical study and post marketing data there are no indications that the safety profile is different in different subsets of the paediatric population or different from the safety profile in adult patients.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p><u>To reports any side effect(s):</u><br />&middot; <strong><em>Saudi Arabia</em></strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;margin-left:-3.7pt;margin-top:1.45pt;
 width:435.75pt;height:61.5pt;z-index:251656704;visibility:visible;
 mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>The National Pharmacovigilance and Drug Safety Centre (NPC):</p><p>o SFDA Call Center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot; <strong><em>Other GCC States:</em></strong></p><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_1"
 o:spid="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
 margin-left:-3.7pt;margin-top:1.4pt;width:441pt;height:21.6pt;z-index:251657728;
 visibility:visible;mso-width-relative:margin;mso-height-relative:margin'
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>- Please contact the relevant competent authority.</p></td></tr></tbody></table></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Accidental ingestion of nitisinone by individuals eating normal diets not restricted in tyrosine and phenylalanine will result in elevated tyrosine levels. Elevated tyrosine levels have been associated with toxicity to eyes, skin, and the nervous system. Restriction of tyrosine and phenylalanine in the diet should limit toxicity associated with this type of tyrosinemia. No information about specific treatment of overdose is available.</strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other alimentary tract and metabolism products, Various alimentary tract and metabolism products, ATC code: A16A X04.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Nitisinone is a competitive inhibitor of 4‑hydroxyphenylpyruvate dioxygenase, the second step in the tyrosine metabolism. By inhibiting the normal catabolism of tyrosine in patients with HT‑1 and AKU, nitisinone prevents the accumulation of harmful metabolites downstream of 4‑hydroxyphenylpyruvate dioxygenase.</p><p>&nbsp;</p><p>The biochemical defect in HT‑1 is a deficiency of fumarylacetoacetate hydrolase, which is the final enzyme of the tyrosine catabolic pathway. Nitisinone prevents the accumulation of the toxic intermediates maleylacetoacetate and fumarylacetoacetate. These intermediates are otherwise converted to the toxic metabolites succinylacetone and succinylacetoacetate. Succinylacetone inhibits the porphyrin synthesis pathway leading to the accumulation of 5‑aminolevulinate.</p><p>&nbsp;</p><p>The biochemical defect in AKU is a deficiency of homogentisate 1,2&nbsp;dioxygenase, the third enzyme of the tyrosine catabolic pathway. Nitisinone prevents the accumulation of the harmful metabolite homogentisic acid (HGA), which otherwise leads to ochronosis of joints and cartilage and thereby the development of the clinical features of the disease.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>In patients with HT-1, nitisinone treatment leads to normalised porphyrin metabolism with normal erythrocyte porphobilinogen synthase activity and urine 5‑aminolevulinate, decreased urinary excretion of succinylacetone, increased plasma tyrosine concentration and increased urinary excretion of phenolic acids. Available data from a clinical study indicates that in more than 90% of the patients urine succinylacetone was normalized during the first week of treatment. Succinylacetone should not be detectable in urine or plasma when the nitisinone dose is properly adjusted.</p><p>&nbsp;</p><p>In patients with AKU, nitisinone treatment reduces the accumulation of HGA. Available data from a clinical study shows a 99.7% reduction of urinary HGA, and a 98.8% reduction of serum HGA, following nitisinone treatment compared to untreated control patients after 12 months of treatment.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety in HT-1</u></p><p>The clinical study was open-labelled and uncontrolled. The dosing frequency in the study was twice daily. Survival probabilities after 2, 4 and 6 years of treatment with nitisinone are summarized in the table below.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>NTBC study (N=250)</p></td></tr><tr><td style="vertical-align:top"><p>Age at start of treatment</p></td><td style="vertical-align:top"><p>2 years</p></td><td style="vertical-align:top"><p>4 years</p></td><td style="vertical-align:top"><p>6 years</p></td></tr><tr><td style="vertical-align:top"><p>&le; 2 months</p></td><td style="vertical-align:top"><p>93%</p></td><td style="vertical-align:top"><p>93%</p></td><td style="vertical-align:top"><p>93%</p></td></tr><tr><td style="vertical-align:top"><p>&le; 6 months</p></td><td style="vertical-align:top"><p>93%</p></td><td style="vertical-align:top"><p>93%</p></td><td style="vertical-align:top"><p>93%</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 6 months</p></td><td style="vertical-align:top"><p>96%</p></td><td style="vertical-align:top"><p>95%</p></td><td style="vertical-align:top"><p>95%</p></td></tr><tr><td style="vertical-align:top"><p>Overall</p></td><td style="vertical-align:top"><p>94%</p></td><td style="vertical-align:top"><p>94%</p></td><td style="vertical-align:top"><p>94%</p></td></tr></tbody></table><p>&nbsp;</p><p>Data from a study used as a historical control (van Spronsen et al., 1994) showed the following survival probability.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Age at onset of symptoms</p></td><td style="vertical-align:top"><p>1 year</p></td><td style="vertical-align:top"><p>2 years</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 2 months</p></td><td style="vertical-align:top"><p>38%</p></td><td style="vertical-align:top"><p>29%</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 2-6 months</p></td><td style="vertical-align:top"><p>74%</p></td><td style="vertical-align:top"><p>74%</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 6 months</p></td><td style="vertical-align:top"><p>96%</p></td><td style="vertical-align:top"><p>96%</p></td></tr></tbody></table><p>&nbsp;</p><p>Treatment with nitisinone was also found to result in reduced risk for the development of hepatocellular carcinoma compared to historical data on treatment with dietary restriction alone. It was found that the early initiation of treatment resulted in a further reduced risk for the development of hepatocellular carcinoma.</p><p>&nbsp;</p><p>The 2-, 4-, and 6‑year probability of no occurrence of HCC during nitisinone treatment for patients aged 24&nbsp;months or younger at the start of treatment and for those older than 24&nbsp;months at the start of treatment is shown in the following table:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:604px"><tbody><tr><td colspan="8" style="vertical-align:top"><p>NTBC study (N=250)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>Number of patients at</p></td><td colspan="3" style="vertical-align:top"><p>Probability of no HCC (95%&nbsp;confidence interval) at</p></td></tr><tr><td style="vertical-align:top"><p>start</p></td><td style="vertical-align:top"><p>2 years</p></td><td style="vertical-align:top"><p>4 years</p></td><td style="vertical-align:top"><p>6 years</p></td><td style="vertical-align:top"><p>2 years</p></td><td style="vertical-align:top"><p>4 years</p></td><td style="vertical-align:top"><p>6 years</p></td></tr><tr><td style="vertical-align:top"><p>All patients</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>155</p></td><td style="vertical-align:top"><p>86</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>98%</p><p>(95; 100)</p></td><td style="vertical-align:top"><p>94%</p><p>(90; 98)</p></td><td style="vertical-align:top"><p>91%</p><p>(81; 100)</p></td></tr><tr><td style="vertical-align:top"><p>Start age &le;&nbsp;24 months</p></td><td style="vertical-align:top"><p>193</p></td><td style="vertical-align:top"><p>114</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>99%</p><p>(98; 100)</p></td><td style="vertical-align:top"><p>99%</p><p>(97; 100)</p></td><td style="vertical-align:top"><p>99%</p><p>(94; 100)</p></td></tr><tr><td style="vertical-align:top"><p>Start age &gt;&nbsp;24 months</p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>92%</p><p>(84; 100)</p></td><td style="vertical-align:top"><p>82%</p><p>(70; 95)</p></td><td style="vertical-align:top"><p>75%</p><p>(56; 95)</p></td></tr></tbody></table><p>&nbsp;</p><p>In an international survey of patients with HT-1 on treatment with dietary restriction alone, it was found that HCC had been diagnosed in 18% of all patients aged 2&nbsp;years and above.</p><p>&nbsp;</p><p>A study to evaluate the PK, efficacy and safety of once daily dosing compared to twice daily dosing was performed in 19 patients with HT‑1. There were no clinically important differences in AEs or other safety assessments between once and twice daily dosing. No patient had detectable succinylacetone (SA) levels at the end of the once-daily treatment period. The study indicates that once daily administration is safe and efficacious across all ages of patients. Data is, however, limited in patients with body weight &lt;20&nbsp;kg.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety in AKU</u></p><p>The efficacy and safety of 10&nbsp;mg once daily nitisinone in the treatment of adult patients with AKU have been demonstrated in a randomized, evaluator-blinded, no-treatment controlled, parallel-group 48-months study in 138 patients (69 treated with nitisinone). The primary endpoint was the effect on urinary HGA levels; a 99.7% reduction following nitisinone treatment compared to untreated control patients was seen after 12 months. Treatment with nitisinone was shown to have a statistically significant positive effect on cAKUSSI, eye pigmentation, ear pigmentation, osteopenia of the hip, and number of spinal regions with pain compared to the untreated control. cAKUSSI is a composite score including eye and ear pigmentation, kidney and prostate stones, aortic stenosis, osteopenia, bone fractures, tendon/ligament/muscle ruptures, kyphosis, scoliosis, joint replacements, and other manifestations of AKU. Thus, the lowered HGA levels in nitisinone-treated patients resulted in a reduction of the ochronotic process and reduced clinical manifestations, supporting a decreased disease progression.</p><p>&nbsp;</p><p>Ocular events, such as keratopathy and eye pain, infections, headache and weight gain were reported with a higher incidence in nitisinone-treated than in untreated patients. Keratopathy led to temporary or permanent treatment discontinuation in 14% of nitisinone-treated patients but was reversible upon withdrawal of nitisinone.</p><p>&nbsp;</p><p>No data is available for patients &gt;&nbsp;70&nbsp;years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Formal absorption, distribution, metabolism and elimination studies have not been performed with nitisinone. In 10 healthy male volunteers, after administration of a single dose of nitisinone capsules (1&nbsp;mg/kg body weight) the terminal half-life (median) of nitisinone in plasma was 54 hours (ranging from 39 to 86&nbsp;hours). A population pharmacokinetic analysis has been conducted on a group of 207&nbsp;HT-1 patients. The clearance and half‑life were determined to be 0.0956&nbsp;l/kg body weight/day and 52.1 hours respectively.<em> </em></p><p><em>&nbsp;</em></p><p><em>In vitro</em> studies using human liver microsomes and cDNA-expressed P450 enzymes have shown limited CYP3A4‑mediated metabolism.</p><p>&nbsp;</p><p>Based on data from a clinical interaction study with 80 mg nitisinone at steady-state, nitisinone caused a 2.3‑fold increase in AUC<sub>&infin;</sub> of the CYP2C9 substrate tolbutamide, which is indicative of a moderate inhibition of CYP2C9. Nitisinone caused an approximate 30% decrease in chlorzoxazone AUC<sub>&infin;</sub>, indicative of a weak induction of CYP2E1. Nitisinone does not inhibit CYP2D6 since metoprolol AUC<sub>&infin;</sub> was not affected by the administration of nitisinone. Furosemide AUC<sub>&infin;</sub> was increased 1.7‑fold, indicating a weak inhibition of OAT1/OAT3 (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p>Based on <em>in vitro</em> studies, nitisinone is not expected to inhibit CYP1A2, 2C19 or 3A4-mediated metabolism or to induce CYP1A2, 2B6 or 3A4/5. Nitisinone is not expected to inhibit P-gp, BCRP or OCT2-mediated transport. Nitisinone plasma concentration reached in clinical setting is not expected to inhibit OATP1B1, OATP1B3 mediated transport.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Nitisinone has shown embryo‑foetal toxicity in the mouse and rabbit at clinically relevant dose levels. In the rabbit, nitisinone induced a dose‑related increase in malformations (umbilical hernia and gastroschisis) from a dose level 2.5‑fold higher than the maximum recommended human dose (2&nbsp;mg/kg/day).</em></strong></p><p><strong><em>A pre- and postnatal development study in the mouse showed statistically significantly reduced pup survival and pup growth during the weaning period at dose levels 125- and 25‑fold higher, respectively, than the maximum recommended human dose, with a trend toward a negative effect on pup survival starting from the dose of 5&nbsp;mg/kg/day. In rats, exposure via milk resulted in reduced mean pup weight and corneal lesions. </em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>No mutagenic but a weak clastogenic activity was observed in </em></strong><strong>in vitro<em> studies. There was no evidence of </em>in vivo<em> genotoxicity (mouse micronucleus assay and mouse liver unscheduled DNA synthesis assay).</em></strong><strong><em> </em></strong><strong><em>Nitisinone did not show carcinogenic potential in a 26-week carcinogenicity study in transgenic mice (TgrasH2).</em></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content</u></p><p>Starch, pregelatinised (maize)</p><p><u>&nbsp;</u></p><p><u>Capsule shell</u></p><p>gelatin</p><p>titanium dioxide (E 171)</p><p>&nbsp;</p><p><u>Printing ink</u></p><p>black iron oxide (E 172)</p><p>shellac</p><p>propylene glycol</p><p>ammonium hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
During the shelf life, the patient may store the capsules for a single period of 2 months (for 2 mg capsules) or 3 months (for 5 mg, 10 mg and 20 mg capsules) at a temperature not above 25°C, after which the medicinal product must be discarded.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HDPE bottle with a tamper‑proof closure of LDPE, containing 60 capsules.</p><p>Each pack contains 1&nbsp;bottle.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Swedish Orphan Biovitrum International AB
SE-112 76 Stockholm
Sweden

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                22/10/2020

THIS IS A MEDICAMENT
•	Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.
•	Follow strictly the doctor's prescription, the method of use and the instructions of the pharmacist who sold the medicament. 
•	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
•	Do not by yourself interrupt the period of treatment prescribed.
•	Do not repeat the same prescription without consulting your doctor.
•	Keep all medicaments out of the reach of children.

Council of Arab Health Ministers, Union of Arab Pharmacists
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>